Adding human complex-type sugar chains to somatostatin analogs made them metabolically stable while maintaining high binding affinity to all five somatostatin receptor subtypes — something existing somatostatin drugs cannot achieve.
All 5 receptor subtypes retainedUnlike current somatostatin drugs that lose affinity for most receptors when modified for stability, glycosylated analogs maintained high binding to all sst1-5 subtypes
What the researchers found
Chemical glycosylation of somatostatin analogs with human complex-type N-glycans (oligosaccharides) achieved two goals simultaneously:
1. Metabolic stability — the glycosylated analogs resisted the rapid plasma degradation that limits native somatostatin's clinical use
2. Broad receptor affinity — the analogs maintained high binding affinity to all five somatostatin receptor subtypes (sst1-5)
This is notable because existing somatostatin drugs (like octreotide and lanreotide) sacrifice broad receptor coverage for stability — they are metabolically stable but only bind strongly to sst2 and sst5. The glycosylated analogs achieve both properties. The authors conclude that chemical glycosylation is a powerful general strategy for improving peptide and protein drug candidates.
Why it matters
Current somatostatin analogs like octreotide (used for acromegaly, carcinoid tumors, and other conditions) only target a subset of somatostatin receptors. Many diseases involve multiple receptor subtypes, meaning current drugs miss part of the therapeutic effect. A stable analog that activates all five receptors could be more effective for conditions where multiple receptor subtypes contribute — and could open entirely new therapeutic indications. The glycosylation approach could also be applied to improve many other peptide drugs.
How the study worked
The researchers synthesized somatostatin analogs and chemically attached human complex-type oligosaccharides (N-glycans) to them. The glycosylated analogs were assessed for metabolic stability (resistance to plasma degradation) and binding affinity to all five somatostatin receptor subtypes (sst1-5). Pharmacokinetic profiles were evaluated to determine improved drug properties compared to native somatostatin.
What this study cannot tell us
The abstract does not provide specific quantitative data on binding affinities, half-life extension, or pharmacokinetic parameters. No in vivo efficacy studies in disease models are described — only drug property characterization. The complexity of synthesizing glycosylated peptides at scale could be a manufacturing challenge. Whether the broad receptor profile translates to clinical advantages over existing selective analogs remains to be demonstrated. No safety or toxicity data are mentioned.
How to read the evidence
This is a drug chemistry study demonstrating improved properties of glycosylated peptide analogs. While the approach is promising, only in vitro binding and stability data are described — no disease model efficacy or clinical data are presented. The evidence is at the early preclinical stage.
When this study was published
Published in 2023, this study represents a current approach in the active field of peptide drug optimization. Chemical glycosylation as a half-life extension strategy is still emerging relative to more established methods.
The bigger picture
Glycosylation — adding sugar chains to proteins — is nature's own strategy for extending protein half-life and modulating function (most antibodies are glycosylated). Applying this to small peptides is a newer approach that competes with other half-life extension strategies like PEGylation (adding polyethylene glycol) and fatty acid attachment (used in semaglutide). If glycosylation can consistently improve peptide drugs without compromising activity, it could become a standard tool in the peptide drug developer's toolkit.
Questions still open
- Would glycosylated somatostatin analogs show superior efficacy over octreotide or lanreotide in diseases where multiple sst receptors are involved?
- Can the chemical glycosylation approach be scaled to pharmaceutical manufacturing, or is it limited to research quantities?
- Could this glycosylation strategy be applied to other short-lived therapeutic peptides like GLP-1, oxytocin, or vasopressin?
Common questions
What is somatostatin and what is it used for?
How does adding sugar molecules make peptides work better as drugs?
Read the original research
Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.
Chemistry (Weinheim an der Bergstrasse, Germany), 29(31), e202300111
Citation
Ochiai, Hirofumi; Shimoda, Taiji; Fukae, Kazuhiro; Maeda, Masatoshi; Ishii, Kazuyuki; Yoshida, Kenta; Tezuka, Katsunari; Tazuru, Keisuke; Saijo, Hayato; Asai, Hiroaki; Kanatani, Akio; Nishiuchi, Yuji. (2023). Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.. Chemistry (Weinheim an der Bergstrasse, Germany), 29(31), e202300111. https://doi.org/10.1002/chem.202300111